ClinicalTrials.Veeva

Menu

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Enrolling
Phase 2

Conditions

Dermatitis, Atopic

Treatments

Drug: GSK1070806
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05999799
2023-505414-15-00 (Other Identifier)
219538

Details and patient eligibility

About

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

Enrollment

175 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult participants 18 years to 75 years of age

  • Participants with:

    • AtD defined by the AAD Consensus Criteria.
    • Diagnosis of AtD ≥1 year.
    • An IGA score ≥3.
    • AtD involvement of ≥10% body surface area (BSA).
    • EASI score ≥16
    • Baseline pruritus numerical rating scale average score for maximum intensity of at least 3.
  • Participants may have had exposure to 1 biologic therapy meeting at least 1 of the following conditions:

    • Participants who stopped treatment due to non-response, partial response, loss of efficacy.
    • Participants who stopped treatment due to intolerance or AEs.
    • Participants who stopped treatment due to cost or loss of access.
  • Participant with a recent history less than or equal to (≤6) months prior to the Screening visit) of inadequate response to a stable regimen of prescription topical medication.

  • Participants for whom prescription topical medications are not tolerated.

  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical study

Exclusion criteria

  • Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, anti-protozoal, or antifungals within 4 weeks before the Screening visit or anytime between the Screening and Baseline visits.
  • Superficial skin infections within 1 week before the Screening visit or active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed)
  • Known, pre-existing or suspected parasitic infection within 6 months before the Screening visit.
  • Symptomatic herpes zoster within 3 months prior to screening
  • Uncontrolled hypertension.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  • Known or suspected history of immunosuppression, including history of invasive opportunistic infections despite infection resolution or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment.
  • Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
  • Breast cancer within the past 10 years.
  • History or presence of significant medical illness including but not limited to cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological, or psychiatric disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments.
  • Previously treated with any oral Janus Kinase inhibitor (JAKi) or other kinase inhibitors, experimental or approved.
  • Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma.
  • Presence of Hepatitis B surface antibody (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to starting study intervention.
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Positive HIV antibody test.
  • Evidence of active or latent TB as documented by medical history, examination, and TB testing with a positive QuantiFERON test at initial Screening visit.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

175 participants in 5 patient groups, including a placebo group

GSK1070806 Dose 1
Experimental group
Description:
Participants will receive GSK1070806 dose 1.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 2
Experimental group
Description:
Participants will receive GSK1070806 dose 2.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 3
Experimental group
Description:
Participants will receive GSK1070806 dose 3.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 4
Experimental group
Description:
Participants will receive GSK1070806 dose 4.
Treatment:
Drug: GSK1070806
Placebo
Placebo Comparator group
Description:
Participants will receive placebo.
Treatment:
Drug: Placebo

Trial contacts and locations

93

Loading...

Central trial contact

US GSK Clinical Trials Call Center; EU GSK Clinical Trials Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems